Chromocell Therapeutics Corp (CHRO)
1.34
-0.08
(-5.63%)
USD |
NYAM |
May 31, 16:00
1.41
+0.07
(+5.22%)
After-Hours: 20:00
Chromocell Therapeutics Research and Development Expense (Quarterly): 0.0491M for Sept. 30, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 0.0491M |
| June 30, 2023 | 0.05M |
| March 31, 2023 | 0.1861M |
| December 31, 2022 | 0.2946M |
| Date | Value |
|---|---|
| September 30, 2022 | 0.028M |
| June 30, 2022 | 0.0266M |
| March 31, 2022 | 0.0426M |
| December 31, 2021 | 0.0601M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.0266M
Minimum
Jun 2022
0.2946M
Maximum
Dec 2022
0.0921M
Average
0.0495M
Median
Research and Development Expense (Quarterly) Benchmarks
| iBio Inc | 0.904M |
| Lixte Biotechnology Holdings Inc | 0.1191M |
| PDS Biotechnology Corp | 6.704M |
| Syros Pharmaceuticals Inc | 24.66M |
| Nutriband Inc | 0.5634M |